EGFR and glioblastoma: Oncogenic EGFR mutations and large genetic rearrangements (as observed in glioblastoma, brain, lung, breast, and ovarian cancers) often cause altered receptor endocytosis, which contributes to increased signaling properties (Yarden and Pines, 2012).